KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Interest Expenses (2018 - 2025)

TherapeuticsMD's Interest Expenses history spans 12 years, with the latest figure at $3000.0 for Q3 2025.

  • For Q3 2025, Interest Expenses changed 0.0% year-over-year to $3000.0; the TTM value through Dec 2025 reached $7000.0, down 12.5%, while the annual FY2021 figure was $22.6 million, 21.04% down from the prior year.
  • Interest Expenses reached $3000.0 in Q3 2025 per TXMD's latest filing, up from $2000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $7.6 million in Q2 2021 to a low of -$2.8 million in Q4 2021.
  • Average Interest Expenses over 5 years is $1.9 million, with a median of $20000.0 recorded in 2023.
  • The largest YoY upside for Interest Expenses was 8.1% in 2021 against a maximum downside of 129.96% in 2021.
  • A 5-year view of Interest Expenses shows it stood at -$2.8 million in 2021, then soared by 293.44% to $5.4 million in 2022, then crashed by 99.63% to $20000.0 in 2023, then crashed by 85.0% to $3000.0 in 2024, then changed by 0.0% to $3000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Interest Expenses are $3000.0 (Q3 2025), $2000.0 (Q2 2025), and $2000.0 (Q1 2025).